News
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...
The U.S. Food and Drug Administration (FDA) approved a new, twice-yearly shot — the first and only of its kind — to prevent ...
Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
Summer break brings some new concerns for parents, the medical workers helping the nation's aging homeless population, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results